Kyowa Kirin Archives -

Close Up Of Senior Man Suffering With Parkinsons Diesease

Despite reporting proof-of-concept results in a mid-stage trial, Kyowa Kirin has decided to discontinue development of its Parkinson’s

Kyowa Kirin drops Nourianz follow-up KW-6356 for Parkinson’s

https://pharmaphorum.com/news/kyowa-kirin-drops-nourianz-follow-up-kw-6356-for-parkinsons/

News/ News/ Oncology

NICE changes tack on ‘game changer’ rare cancer therapy Poteligeo

Phil Taylor HEOR, Kyowa Kirin, lymphoma, NHS, NICE, Oncology, Poteligeo 0 Comment

NICE has reversed an earlier decision not to recommend NHS use of Kyowa Kirin’s Poteligeo for two rare

NICE changes tack on ‘game changer’ rare cancer therapy Poteligeo

https://pharmaphorum.com/news/nice-changes-tack-on-game-changer-rare-cancer-therapy-poteligeo/

Market Access/ News/ News

Boost for AZ as Ultomiris gets CHMP nod for expanded label

Phil Taylor Alexion, AstraZeneca, Kyowa Kirin, Nexviadyme, Nouryant, Parkinson's disease, Pompe disease, rare disease, Sanofi Genzyme, Soliris, Ultomiris 0 Comment

Fresh from its takeover of Alexion, AstraZeneca has picked up a recommendation in the EU for an expansion

Boost for AZ as Ultomiris gets CHMP nod for expanded label

https://pharmaphorum.com/news/boost-for-az-as-ultomiris-gets-chmp-nod-for-expanded-label/

Market Access/ News/ News

Scotland backs rare blood cancer drug Poteligeo rejected by NICE

Phil Taylor AstraZeneca, Boehringer Ingelheim, Calquence, Eli Lilly, Kyowa Kirin, NHS, nintedanib, Olumiant, Oncology, Poteligeo, Scotland, Scottish Medicines Consortium, Servier 0 Comment

A north-south divide has emerged in UK medicines access after the Scottish Medicines Consortium (SMC) okayed Kyowa Kirin’s

Scotland backs rare blood cancer drug Poteligeo rejected by NICE

https://pharmaphorum.com/news/scotland-backs-rare-blood-cancer-drug-poteligeo-rejected-by-nice/

News/ News/ R&D

Amgen pays Kyowa $400m upfront for OX40 eczema drug

Phil Taylor Amgen, atopic dermatitis, dermatology, Dupixent, Kyowa Kirin, licensing, OX40, Regeneron, Sanofi 0 Comment

Amgen has made a play in a hot area of immunology R&D, paying $400 million upfront to claim

Amgen pays Kyowa $400m upfront for OX40 eczema drug

https://pharmaphorum.com/news/amgen-pays-kyowa-400m-upfront-for-ox40-eczema-drug/

News/ News/ R&D

Kyowa Kirin backs €125m life science fund closed by Fountain Healthcare

Phil Taylor European biotech, financing, Fountain Healthcare, Kyowa Kirin, Life Sciences, venture capital 0 Comment

Ireland-based Fountain Healthcare Partners has raised another €125 million ($131 million) for its third life sciences fund –

Kyowa Kirin backs €125m life science fund closed by Fountain Healthcare

https://pharmaphorum.com/news/kyowa-kirin-backs-e125m-life-science-fund-closed-by-fountain-healthcare/

News

GSK’s kidney disease anaemia drug approved in Japan, taking on Astellas’ rival

Richard Staines anaemia, Astellas, AstraZeneca, chronic kidney disease, Duvroq, FibroGen, GlaxoSmithKline, Kyowa Kirin 0 Comment

GlaxoSmithKline’s drug for anaemia caused by chronic kidney disease daprodustat has been approved in Japan, taking on a recently approved rival from Astellas. Marketed

GSK’s kidney disease anaemia drug approved in Japan, taking on Astellas’ rival

https://pharmaphorum.com/news/gsk-kidney-disease-anaemia-drug-approved-in-japan-taking-on-astellas-rival/

News

FDA approves Kyowa Kirin’s new Parkinson’s drug Nourianz

Richard Staines Kyowa Kirin, neurology, Parkinson's 0 Comment

The FDA has approved a new drug for Parkinson’s disease, giving the nod to Kyowa Kirin’s Nourianz (istadefylline)

FDA approves Kyowa Kirin’s new Parkinson’s drug Nourianz

https://pharmaphorum.com/news/fda-approves-kyowa-kirins-new-parkinsons-drug-nourianz/

News/ News/ R&D

Could Kyowa Kirin be eyeing ophthalmology use for cancer drug tivozanib?

Richard Staines cancer, Kyowa Kirin, ophthalmology 0 Comment

Kyowa Kirin has bought back rights outside of cancer to tivozanib, amending an agreement dating back to 2006

Could Kyowa Kirin be eyeing ophthalmology use for cancer drug tivozanib?

https://pharmaphorum.com/news/could-kyowa-kirin-be-eyeing-ophthalmology-use-for-cancer-drug-tivozanib/

Trending

Kyowa Kirin

Login